CTS Q3 2026 slides: record margins fuel guidance raise

CTS acquired Millar for $50M, expecting $30M annual revenue and EPS accretion by H2 2027. Millar's medical and sensing capabilities complement CTS's portfolio. Q3 saw mixed segment performance, with aerospace/defense up 30% QoQ. CTS raised 2026 guidance to $580M-$590M sales and $2.78-$2.88 EPS, citing diversified demand.

CTS Corporation (CTS) reported Q3 2026 revenue of $150M, up 5%, with gross margin at 42.2%, adjusted EBITDA margin at 24.7%, and adjusted diluted EPS. The company raised 2026 guidance to $580M-$590M in sales and $2.78-$2.88 adjusted EPS, citing strong execution and the integration of the Millar acquisition.

CTS reported Q3 2026 earnings with record gross margin at 42.2% and adjusted EPS at $0.77. The company acquired Millar, expecting $30M annual revenue, and raised full-year guidance to $580M-$590M sales and $2.78-$2.88 adjusted EPS. Medical, industrial, and transportation markets showed growth, with medical up 21% YoY. The acquisition is expected to be accretive in H2 2027.

CTS Corporation (NYSE: CTS) shares rose 4.5% after reporting Q3 2026 results with revenue of $149.6M, net income of $17.8M, and EPS of $0.77, all above estimates. The company raised its full-year revenue and earnings guidance, exceeding consensus forecasts. The stock has gained 29.1% year-to-date but remains 17.1% below its 52-week high.

CTS stock surged 4.6% in pre-market trading after reporting Q3 earnings that exceeded expectations. Adjusted EPS was $0.77, up from the $0.65 consensus, and sales rose 5% YoY to $149.6M. The company raised its 2026 guidance for EPS and sales, citing strong demand and a recent acquisition of Millar Holdings for $50M.

CTS Corp (NYSE: CTS) reported Q3 EPS of $0.77, beating estimates by $0.10, with revenue at $149.58M, exceeding expectations. The company guided FY 2026 EPS to $2.78-$2.88 and revenue to $580.00M-$590.00M, both above consensus. The stock is down 15.91% over 3 months but up 33.10% year-over-year.